Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

Annals of Oncology

Volumn 25, Issue 11, 2014, Pages 2277-2284

  Lebbé, Celeste ^a   Weber, J S ^b   Maio, M ^c   Neyns, B ^d   Harmankaya, K ^e,k   Hamid, O ^f   O'Day, S J ^g   Konto, C ^h   Cykowski, L ^h   McHenry, M B ⁱ   Wolchok, J D ^j  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e Universitatsklinik fur Dermatologie   (Austria)

^f Angeles Clinic and Research Institute   (United States)

^g Beverly Hills Cancer Center   (United States)

^h Neuroscience Global Clinical Research   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k DANUBE HOSPITAL   (Austria)

more..

Author keywords

Advanced melanoma; Cytotoxic T lymphocyte antigen 4; Immunotherapy; Ipilimumab; Long term survival; Survival rate

Indexed keywords

IPILIMUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ARTICLE; COLITIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY; IMMUNOPATHOLOGY; INTERSTITIAL LUNG DISEASE; LIVER DISEASE; LONG TERM SURVIVAL; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MELANOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETREATMENT; SKIN DISEASE; SURVIVAL RATE; ADULT; ADVERSE DRUG REACTION; AGED; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SKIN NEOPLASMS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 84923266973     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu441     Document Type: Article

References (23)

1. Garbe C, Eigentler TK, Keilholz U et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5-24.
2. Maio M, Bondarenko I, Robert C et al. Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma. In Presented at the European Cancer Congress 2013, 27 September-1 October 2013 (Abstr 3704). Amsterdam, The Netherlands 2013.
3. Wolchok JD, Weber JS, Maio M et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24: 2174-2180.
4. Hoos A, Ibrahim R, Korman A et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37: 533-546.
5. Wolchok JD, Hodi FS, Weber JS et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 2013; 1291: 1-13.
6. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
7. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
8. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
9. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6: S11-S14.
10. Prieto PA, Yang JC, Sherry RM et al. CTLA-4 blockade with ipilimumab: longterm follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-2047.
11. Weber JS, O'Day S, Urba W et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26: 5950-5956.
12. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebocontrolled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-5598.
13. O'Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-1717.
14. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164.
15. Hamid O, Schmidt H, Nissan A et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9: 204.
16. Hersh EM, O'Day SJ, Powderly J et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2011; 29: 489-498.
17. Chiarion-Sileni V, Pigozzo J, Ascierto PA et al. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer 2014; 110: 1721-1726.
18. Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. In Presented at the European Cancer Congress 2013, 27 September-1 October 2013 (Abstr 24LBA). Amsterdam, The Netherlands 2013.
19. Robert C, Schadendorf D, Messina M et al. MDX010-20 investigators. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013; 19: 2232-2239.
20. Ibrahim RA, Berman DM, DePril V et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011; 29: Abstr 8583.
21. YERVOY™ (ipilimumab) US Prescribing Information: Risk Evaluation and Mitigation Strategy. Bristol-Myers Squibb Company; 2011; http://www.yervoy.com/hcp/rems. aspx (June 2014, date last accessed).
22. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697.
23. Feng Y, Roy A, Masson E et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 2013; 19: 3977-3986.